COVID-19: potential therapeutics for pediatric patients
<p>The global spread of COVID-19 has imparted significant economic, medical, and social burdens. Like adults, children are affected by this pandemic. However, milder clinical symptoms are often experienced by them. Only a minimal proportion of the affected patients may develop severe and compl...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513567038898176 |
|---|---|
| author | Nour K. Younis (14152512) |
| author2 | Rana O. Zareef (14152515) Ghina Fakhri (14152518) Fadi Bitar (295982) Ali H. Eid (5461829) Mariam Arabi (6339860) |
| author2_role | author author author author author |
| author_facet | Nour K. Younis (14152512) Rana O. Zareef (14152515) Ghina Fakhri (14152518) Fadi Bitar (295982) Ali H. Eid (5461829) Mariam Arabi (6339860) |
| author_role | author |
| dc.creator.none.fl_str_mv | Nour K. Younis (14152512) Rana O. Zareef (14152515) Ghina Fakhri (14152518) Fadi Bitar (295982) Ali H. Eid (5461829) Mariam Arabi (6339860) |
| dc.date.none.fl_str_mv | 2022-11-22T21:16:30Z |
| dc.identifier.none.fl_str_mv | 10.1007/s43440-021-00316-1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/COVID-19_potential_therapeutics_for_pediatric_patients/21598014 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Paediatrics Pharmacology and pharmaceutical sciences Pharmacology General Medicine |
| dc.title.none.fl_str_mv | COVID-19: potential therapeutics for pediatric patients |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>The global spread of COVID-19 has imparted significant economic, medical, and social burdens. Like adults, children are affected by this pandemic. However, milder clinical symptoms are often experienced by them. Only a minimal proportion of the affected patients may develop severe and complicated COVID-19. Supportive treatment is recommended in all patients. Antiviral and immunomodulatory medications are spared for hospitalized children with respiratory distress or severe to critical disease. Up till now, remdesivir is the only USFDA-approved anti-COVID-19 medication indicated in the majority of symptomatic patients with moderate to severe disease. Dexamethasone is solely recommended in patients with respiratory distress maintained on oxygen or ventilatory support. The use of these medications in pediatric patients is founded on evidence deriving from adult studies. No randomized controlled trials (RCTs) involving pediatric COVID-19 patients have assessed these medications’ efficacy and safety, among others. Similarly, three novel monoclonal anti-SARS-CoV-2 spike protein antibodies, bamlanivimab, casirivimab and imdevimab, have been recently authorized by the USFDA. Nonetheless, their efficacy has not been demonstrated by multiple RCTs. In this review, we aim to dissect the various potential therapeutics used in children with COVID-19. We aspire to provide a comprehensive review of the available evidence and display the mechanisms of action and the pharmacokinetic properties of the studied therapeutics. Our review offers an efficient and practical guide for treating children with COVID-19.</p><h2>Other Information</h2> <p> Published in: Pharmacological Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s43440-021-00316-1" target="_blank">http://dx.doi.org/10.1007/s43440-021-00316-1</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a3573fb9b19e9b8bda72eb2383f49870 |
| identifier_str_mv | 10.1007/s43440-021-00316-1 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21598014 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | COVID-19: potential therapeutics for pediatric patientsNour K. Younis (14152512)Rana O. Zareef (14152515)Ghina Fakhri (14152518)Fadi Bitar (295982)Ali H. Eid (5461829)Mariam Arabi (6339860)PaediatricsPharmacology and pharmaceutical sciencesPharmacologyGeneral Medicine<p>The global spread of COVID-19 has imparted significant economic, medical, and social burdens. Like adults, children are affected by this pandemic. However, milder clinical symptoms are often experienced by them. Only a minimal proportion of the affected patients may develop severe and complicated COVID-19. Supportive treatment is recommended in all patients. Antiviral and immunomodulatory medications are spared for hospitalized children with respiratory distress or severe to critical disease. Up till now, remdesivir is the only USFDA-approved anti-COVID-19 medication indicated in the majority of symptomatic patients with moderate to severe disease. Dexamethasone is solely recommended in patients with respiratory distress maintained on oxygen or ventilatory support. The use of these medications in pediatric patients is founded on evidence deriving from adult studies. No randomized controlled trials (RCTs) involving pediatric COVID-19 patients have assessed these medications’ efficacy and safety, among others. Similarly, three novel monoclonal anti-SARS-CoV-2 spike protein antibodies, bamlanivimab, casirivimab and imdevimab, have been recently authorized by the USFDA. Nonetheless, their efficacy has not been demonstrated by multiple RCTs. In this review, we aim to dissect the various potential therapeutics used in children with COVID-19. We aspire to provide a comprehensive review of the available evidence and display the mechanisms of action and the pharmacokinetic properties of the studied therapeutics. Our review offers an efficient and practical guide for treating children with COVID-19.</p><h2>Other Information</h2> <p> Published in: Pharmacological Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s43440-021-00316-1" target="_blank">http://dx.doi.org/10.1007/s43440-021-00316-1</a></p>2022-11-22T21:16:30ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s43440-021-00316-1https://figshare.com/articles/journal_contribution/COVID-19_potential_therapeutics_for_pediatric_patients/21598014CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215980142022-11-22T21:16:30Z |
| spellingShingle | COVID-19: potential therapeutics for pediatric patients Nour K. Younis (14152512) Paediatrics Pharmacology and pharmaceutical sciences Pharmacology General Medicine |
| status_str | publishedVersion |
| title | COVID-19: potential therapeutics for pediatric patients |
| title_full | COVID-19: potential therapeutics for pediatric patients |
| title_fullStr | COVID-19: potential therapeutics for pediatric patients |
| title_full_unstemmed | COVID-19: potential therapeutics for pediatric patients |
| title_short | COVID-19: potential therapeutics for pediatric patients |
| title_sort | COVID-19: potential therapeutics for pediatric patients |
| topic | Paediatrics Pharmacology and pharmaceutical sciences Pharmacology General Medicine |